These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38791198)

  • 1. ABCG2 Mediates Resistance to the Dual EGFR and PI3K Inhibitor MTX-211 in Cancer Cells.
    Wu CP; Hung CY; Murakami M; Wu YS; Chu YH; Huang YH; Yu JS; Ambudkar SV
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells.
    Wu ZX; Mai Q; Yang Y; Wang JQ; Ma H; Zeng L; Chen ZS; Pan Y
    Biomed Pharmacother; 2021 Apr; 136():111223. PubMed ID: 33450491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines.
    Wu CP; Hung CY; Lusvarghi S; Huang YH; Tseng PJ; Hung TH; Yu JS; Ambudkar SV
    Biochem Pharmacol; 2020 Oct; 180():114137. PubMed ID: 32634436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
    Wu CP; Li YQ; Chi YC; Huang YH; Hung TH; Wu YS
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines.
    Wu CP; Hung CY; Hsieh YJ; Murakami M; Huang YH; Su TY; Hung TH; Yu JS; Wu YS; Ambudkar SV
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
    Wu CP; Murakami M; Hsiao SH; Chou AW; Li YQ; Huang YH; Hung TH; Ambudkar SV
    Mol Pharm; 2017 Jul; 14(7):2368-2377. PubMed ID: 28597653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo.
    Chen Z; Chen Y; Xu M; Chen L; Zhang X; To KK; Zhao H; Wang F; Xia Z; Chen X; Fu L
    Mol Cancer Ther; 2016 Aug; 15(8):1845-58. PubMed ID: 27196753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
    Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
    Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.
    Wu CP; Hsiao SH; Murakami M; Lu MJ; Li YQ; Hsieh CH; Ambudkar SV; Wu YS
    Cancer Lett; 2017 Nov; 409():56-65. PubMed ID: 28893612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
    Wang L; Lin N; Li Y
    Oncol Rep; 2019 Mar; 41(3):1678-1690. PubMed ID: 30664164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
    Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
    Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
    Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
    Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
    Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.
    Wu CP; Murakami M; Wu YS; Lin CL; Li YQ; Huang YH; Hung TH; Ambudkar SV
    Biomed Pharmacother; 2022 May; 149():112922. PubMed ID: 36068781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2.
    Inoue Y; Morita T; Onozuka M; Saito KI; Sano K; Hanada K; Kondo M; Nakamura Y; Kishino T; Nakagawa H; Ikegami Y
    Cells; 2019 Jul; 8(7):. PubMed ID: 31340525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.